Stocks and Investing Stocks and Investing
Tue, June 25, 2024

Geoff Meacham Maintained (BBIO) at Strong Buy with Decreased Target to $42 on, Jun 25th, 2024


Published on 2024-10-28 12:04:49 - WOPRAI, Geoff Meacham
  Print publication without navigation


Geoff Meacham of B of A Securities, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $50 to $42 on, Jun 25th, 2024.

Geoff has made no other calls on BBIO in the last 4 months.



There are 6 other peers that have a rating on BBIO. Out of the 6 peers that are also analyzing BBIO, 0 agree with Geoff's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Geoff


  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $43 on, Thursday, June 20th, 2024
  • Eliana Merle of "UBS" Maintained at Strong Buy with Decreased Target to $47 on, Tuesday, May 28th, 2024
  • Josh Schimmer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $70 on, Tuesday, May 28th, 2024
  • Cory Kasimov of "Evercore ISI Group" Initiated at Buy and Held Target at $50 on, Tuesday, May 14th, 2024
  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $45 on, Wednesday, March 20th, 2024
  • Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $53 on, Tuesday, March 5th, 2024
Contributing Sources